Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Iovance Biotherapeutics, Inc.

http://www.iovance.com/

Latest From Iovance Biotherapeutics, Inc.

Adaptimmune/Genentech Deal Gives Powerful Push To Solid Tumor Cell Therapies

Adaptimmune is getting a leg up in the race to develop iPSC-derived allogeneic cell therapies in a deal with the Roche subsidiary worth potentially more than $3bn.

Deals Gene Therapy

Eight Oncology Drug Launches Expected In 2022 – Solid Tumors

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are eight new oncology products to treat solid tumors that could make their market debuts next year.

Approvals Cancer

When FDA Changes Your Payment Plans

Five sponsors withdrew their applications for new technology add-on payments from CMS – all due to regulatory reasons happening at the US FDA.

Medicare Drug Review

BioNTech Extends Global Reach, Ambition With Kite’s Neoantigen T-Cell Receptor Assets

The company has already expanded into Asia and shown early clinical data from its own cell therapy programs as it acquires Kite Pharma’s neoantigen TCR R&D program and manufacturing plant.

Deals Biologics
See All

Company Information

  • Industry
  • Biotechnology
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Other Names / Subsidiaries
    • Genesis Biopharma
    • Lion Biotechnologies, Inc. (LBIO)
UsernamePublicRestriction

Register